Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 1,339 shares of common stock for approximately $32,000 as part of a pre-arranged trading plan.

Summary

• Derek J. Maetzold, President and Chief Executive Officer, and a Director of Castle Biosciences Inc., reported a sale of common stock.
• On September 2, 2025, Mr. Maetzold disposed of 1,339 shares of Castle Biosciences common stock.
• The shares were sold at a weighted-average price of $23.93 per share, with individual trades ranging from $23.79 to $24.00.
• This transaction was executed pursuant to a Rule 10b5-1 plan, which was adopted by Mr. Maetzold on May 8, 2025.
• Following this transaction, Mr. Maetzold directly beneficially owns 67,005 shares of common stock.
• Additionally, Mr. Maetzold holds significant indirect beneficial ownership through various trusts, including The Maetzold Descendants 2020 Trust (52,923 shares), Derek Maetzold 2020 Irrevocable Trust (44,986 shares), several Maetzold 2018 Remainder Trusts (totaling 14,463 shares), and DJM Grantor Retained Annuity Trusts (totaling 148,900 shares).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates concerns about the insider's immediate sentiment regarding the company's prospects. It represents a scheduled liquidity event rather than a reactive decision.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a scheduled sale rather than a reaction to recent company performance or news.

Negatives

• A sale of shares by a high-ranking insider, such as the President and CEO, could be perceived negatively by some investors, even if pre-planned.

Risks

• No specific risks related to the company's operations or financial health were disclosed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information that directly relates to broader industry trends or competitive landscape.

Related Party Transactions

• Derek J. Maetzold's indirect beneficial ownership is held through various trusts where he or his family members are trustees and/or beneficiaries, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trusts, and DJM Grantor Retained Annuity Trusts.

Stakeholder Impact

• Shareholders may note the sale by the CEO, but the pre-planned nature of the transaction under Rule 10b5-1 suggests it is not indicative of a change in management's confidence in the company's long-term prospects.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this routine insider transaction.

Key Dates

Keywords

Castle Biosciences, CSTL, Derek J. Maetzold, Insider Sale, Form 4, 10b5-1 Plan, CEO, Director, Stock Transaction